Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
How do you use P1NP in your clinical practice to guide management of osteoporosis?
Related Questions
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
What do you consider as absolute and relative contraindications for the use of romosozumab?
Would you use romosozumab in a patient with a cardiovascular event more than 2 years prior?
Is it safe to give an anabolic agent for osteoporosis without following up with an anti-resorptive agent?
Do you recommend a particular antiresorptive/anabolic agent for patients who are at high risk for fractures but have high risk of osteonecrosis of the jaw?
In a patient with history of atypical femoral fracture while on denosumab how do you sequence further treatment options?
Would you consider PTH-analog therapy in a woman with osteoporotic vertebral fractures who has asymptomatic non-obstructive renal stones and normal 24-hour urine calcium level?
After completing 12 months romosozumab, what is the next best treatment option for patients with severe osteoporosis, high risk for fracture, and normal kidney function?
Do you delay spinal surgery (e.g. lumbar decompression for stenosis) in men or women with newly diagnosed osteoporosis and multiple thoracic compression fractures (not involving site of potential surgery) in order to initiate anabolic or anti-resorptive therapy to potentially improve surgical healing outcomes?
